Table 2. Multivariable analysis of OS and EFS in the first cohort of 129 CN-AML patients.
| Variables in Final Model by End Point | HR | 95% CI | P |
|---|---|---|---|
| OS | |||
| MAP7 expression | 1.7 | 1.05–2.74 | 0.03 |
| NPM1, mutated VS wild type | 0.63 | 0.38–1.05 | 0.07 |
| CEBPA, mutated VS wild type | 0.57 | 0.27–1.21 | 0.14 |
| IDH1, mutated VS wild type | 0.95 | 0.48–1.85 | 0.87 |
| IDH2, mutated VS wild type | 0.58 | 0.25–1.36 | 0.21 |
| EFS | |||
| MAP7 expression | 1.79 | 1.13–2.84 | 0.01 |
| NPM1, mutated VS wild type | 0.52 | 0.31–0.86 | 0.01 |
| CEBPA, mutated VS wild type | 0.69 | 0.35–1.37 | 0.29 |
| FLT3-ITD, presented VS others | 1.6 | 1.0–2.55 | 0.04 |
| IDH1, mutated VS wild type | 1.31 | 0.71–2.4 | 0.39 |
| IDH2, mutated VS wild type | 0.65 | 0.28–1.53 | 0.32 |
HR, hazard ratio; CI, confidence interval.